About This Training Program
We are happy to offer a 3½-day short course to introduce academic researchers to the principles of neurotherapeutics discovery and development.
You will find the course useful if you would like to learn how molecules to treat disorders of the nervous system are identified and evaluated prior to entering clinical trials. The course will be especially relevant if you conduct basic neuroscience research and would like to compete for the many translational grant opportunities that are available.
The course covers the principles of drug discovery and development, including the identification of a lead compound and IND enabling studies. The course considers the discovery and development of small molecule therapies and also includes considerations that apply to biological therapies, such as antibodies, antisense oligonucleotides, gene therapies and cell therapies. The course also addresses the unique challenges inherent in developing treatments for nervous system disorders and the particular challenges that academic neuroscientists are likely to face in planning and conducting therapeutics discovery research. Please note, however, that the course curriculum does not address clinical trials.
Participants who attend the short course program will have access to senior faculty who will assist the trainee to achieve success in their individual drug development projects.
Although we anticipate that most applicants will be advanced postdoctoral fellows or junior faculty members, any academic investigator who would benefit from the course is invited to apply. Basic researchers and clinician scientists are eligible. Mid-career and senior faculty who are interested in pursuing a new research direction of neurotherapeutics discovery and development are encouraged to apply. There is no tuition or registration fee and all travel expenses will be defrayed for successful applicants. The course is offered annually.
We are excited to have the opportunity to offer this course, which we believe will help to advance the availability of new therapies for patients with neurological and psychiatric disorders. If your work would benefit from an understanding of how neurotherapies are discovered, characterized and tested so that they can enter clinical trials, you are encouraged to apply.
Michael A. Rogawski, MD, PhD
Barbara Slusher, PhD
Course Directors
Supported by National Institute of Neurological Disorders and Stroke Grants 1R25NS077582, 1R25NS099170 and 1R25NS129110.
You will find the course useful if you would like to learn how molecules to treat disorders of the nervous system are identified and evaluated prior to entering clinical trials. The course will be especially relevant if you conduct basic neuroscience research and would like to compete for the many translational grant opportunities that are available.
The course covers the principles of drug discovery and development, including the identification of a lead compound and IND enabling studies. The course considers the discovery and development of small molecule therapies and also includes considerations that apply to biological therapies, such as antibodies, antisense oligonucleotides, gene therapies and cell therapies. The course also addresses the unique challenges inherent in developing treatments for nervous system disorders and the particular challenges that academic neuroscientists are likely to face in planning and conducting therapeutics discovery research. Please note, however, that the course curriculum does not address clinical trials.
Participants who attend the short course program will have access to senior faculty who will assist the trainee to achieve success in their individual drug development projects.
Although we anticipate that most applicants will be advanced postdoctoral fellows or junior faculty members, any academic investigator who would benefit from the course is invited to apply. Basic researchers and clinician scientists are eligible. Mid-career and senior faculty who are interested in pursuing a new research direction of neurotherapeutics discovery and development are encouraged to apply. There is no tuition or registration fee and all travel expenses will be defrayed for successful applicants. The course is offered annually.
We are excited to have the opportunity to offer this course, which we believe will help to advance the availability of new therapies for patients with neurological and psychiatric disorders. If your work would benefit from an understanding of how neurotherapies are discovered, characterized and tested so that they can enter clinical trials, you are encouraged to apply.
Michael A. Rogawski, MD, PhD
Barbara Slusher, PhD
Course Directors
Supported by National Institute of Neurological Disorders and Stroke Grants 1R25NS077582, 1R25NS099170 and 1R25NS129110.
History of the Training Program
Course Directors in recent years have been Karl Scheidt, Barbara Slusher and Michael A. Rogawski
The training program is affiliated with the Division of Translational Research of the National Institute of Neurological Disorders and Stroke and the Blueprint Neurotherapeutics Network of the NIH, Program Director: Oreisa O'Neil-Mathurin, MPH.
The training program was first offered February 27 to March 2, 2013. A second offering of the course was held February 19 to 22, 2014. The third offering was held February 18 to 21, 2015. The fourth course offering was held March 16 to 19, 2016 at the Bethesda North Marriott Hotel & Conference Center, North Bethesda, Maryland. The fifth course offering was held March 7 to 11, 2018 at the Hilton Washington DC/Rockville Hotel & Executive Meeting Center in Rockville, Maryland. The first four offering of the course focused exclusively on the discovery and development of small molecule neurotherapeutics. The offering held in 2018 provided training in small molecule therapies but for the first time also included training relevant to biological therapies, including antibody-based therapies, cell-based therapies, and gene-based therapies. The sixth offering, held March 25 to March 28, 2019 at the Bethesda North Marriott Hotel & Conference Center, expanded the coverage of biological therapies. The seventh offering of the course was held March 2 to March 5, 2020 at the Hyatt Regency Bethesda. The eighth offering of the course was held virtually February 8 to 12, 2021. The ninth offering was held March 28 to 31, 2022 at the Conference Center at the University of California, Davis. The tenth offering was held March 14 to 17, 2023 at the Vanderhoef Theatre of the Mondavi Center, University of California, Davis. The eleventh offering was held at the Hyatt Regency Hotel in Bethesda, Maryland from March 12 to 15, 2024.
The training program was first offered February 27 to March 2, 2013. A second offering of the course was held February 19 to 22, 2014. The third offering was held February 18 to 21, 2015. The fourth course offering was held March 16 to 19, 2016 at the Bethesda North Marriott Hotel & Conference Center, North Bethesda, Maryland. The fifth course offering was held March 7 to 11, 2018 at the Hilton Washington DC/Rockville Hotel & Executive Meeting Center in Rockville, Maryland. The first four offering of the course focused exclusively on the discovery and development of small molecule neurotherapeutics. The offering held in 2018 provided training in small molecule therapies but for the first time also included training relevant to biological therapies, including antibody-based therapies, cell-based therapies, and gene-based therapies. The sixth offering, held March 25 to March 28, 2019 at the Bethesda North Marriott Hotel & Conference Center, expanded the coverage of biological therapies. The seventh offering of the course was held March 2 to March 5, 2020 at the Hyatt Regency Bethesda. The eighth offering of the course was held virtually February 8 to 12, 2021. The ninth offering was held March 28 to 31, 2022 at the Conference Center at the University of California, Davis. The tenth offering was held March 14 to 17, 2023 at the Vanderhoef Theatre of the Mondavi Center, University of California, Davis. The eleventh offering was held at the Hyatt Regency Hotel in Bethesda, Maryland from March 12 to 15, 2024.
Participants in the 2020 course offering held at the Hyatt Regency Bethesda.
Participants in the 2016 course offering held at Bethesda North Marriott Hotel & Conference Center.
From the 2016 course offering held at Bethesda North Marriott Hotel & Conference Center.
From the 2016 course offering held at Bethesda North Marriott Hotel & Conference Center.
From the 2015 course offering held at Georgetown University Hotel and Conference Center.
